Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03065764
Recruitment Status : Active, not recruiting
First Posted : February 28, 2017
Last Update Posted : August 17, 2017
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Prof. dr. E.F. Smit, VU University Medical Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : December 1, 2019
  Estimated Study Completion Date : December 1, 2019